What is NovoCure's cash ratio?

NovoCure (NVCR) reported cash ratio of 0.4× in Q1 2026.

How has NovoCure's cash ratio changed year-over-year?

NovoCure's cash ratio increased by 135.0% year-over-year, from 0.2× to 0.4×.

What is the long-term trend for NovoCure's cash ratio?

Over 5 years (2020 to 2025), NovoCure's cash ratio has grown at a -27.3% compound annual growth rate (CAGR), from 2.1× to 0.4×.

What does cash ratio mean?

Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.

NovoCure NVCR Cash ratio

Cash ratio at other companies

Boston ScientificBSX

0.2×+0.1×

MedtronicMDT

0.2×0.0×

Iovance Biotherapeutics, Inc.IOVA

1.5×+0.1×

Nuvation BioNUVB

1.6×+0.7×

Vir Biotechnology, Inc.VIR

3.8×+1.2×

Syndax PharmaceuticalsSNDX

1.5×-0.1×

Other financials

Income statement

See full

Revenue$174.1M+12.3%

Gross profit$135.1M+16.0%

Operating income-$67.4M-78.1%

Net income-$71.1M-107%

EPS (diluted)-$0.62-100%

Balance sheet

See full

Cash & equivalents$87.5M-31.2%

Total debt$39.5M-2.1%

Total equity$330.7M-8.6%

Total assets$787.9M-36.9%

Cash flow

See full

Operating cash flow-$13.5M+62.1%

CapEx$5.2M-51.4%

Free cash flow-$18.7M+59.7%

Valuation

See full

Market cap$1.7B-36.7%

Profitability

See full

Gross margin75.2%-2.0pp

Operating margin-27.2%+0.4pp

Net margin-25.7%-0.7pp

FCF margin-7.1%-2.0pp

Returns & leverage

See full

Return on equity-50%+5.4pp

Debt / equity0.1×0.0×

Current ratio2.9×+1.4×

Where this comes from

Calculated from NovoCure’s reported figures.

cash and equivalents/total current liabilities=0.4×

Based on the most recent quarter.

The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about NovoCure's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NovoCure's cash ratio?: NovoCure (NVCR) reported cash ratio of 0.4× in Q1 2026.
How has NovoCure's cash ratio changed year-over-year?: NovoCure's cash ratio increased by 135.0% year-over-year, from 0.2× to 0.4×.
What is the long-term trend for NovoCure's cash ratio?: Over 5 years (2020 to 2025), NovoCure's cash ratio has grown at a -27.3% compound annual growth rate (CAGR), from 2.1× to 0.4×.
What does cash ratio mean?: Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.